Department of Health Economics and Health Services Research, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
Department of Health Economics and Health Services Research, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
BMJ Open. 2024 Aug 17;14(8):e087003. doi: 10.1136/bmjopen-2024-087003.
The early detection of pancreatic cancer is an important step in reducing mortality by offering patients curative treatment. Screening strategies in risk populations and by means of different detection methods have been economically evaluated. However, a synthesis of screening studies to inform resource allocation towards early detection within the disease area has not been done. Therefore, studies evaluating the cost-effectiveness and costs of screening for pancreatic cancer should be systematically reviewed.
A systematic review of economic evaluations reporting the cost-effectiveness or costs of pancreatic cancer screening will be conducted. The electronic databases Medline, Web of Science and EconLit will be searched without geographical or time restrictions. Two independent reviewers will select eligible studies based on predefined criteria. The study quality will be assessed using the Consolidated Health Economic Evaluation Reporting Standards statement and the Bias in Economic Evaluation checklist. One reviewer will extract relevant data and a second reviewer will cross-check compliance with the extraction sheet. Key items will include characteristics of screened individuals, the screening strategies used, and costs, health effects and cost-effectiveness as study outputs. Differences of opinion between the reviewers will be solved by consulting a third reviewer.
Ethics approval is not required for this study since no original data will be collected. The results will be disseminated through presentations at conferences and publication in a peer-reviewed journal. The results of the systematic review will inform future economic evaluations of pancreatic screening, which provide guidance for decision-making in healthcare resource prioritisation.
CRD42023475348.
通过为患者提供治愈性治疗，早期发现胰腺癌对于降低死亡率至关重要。已经对高危人群和通过不同检测方法进行的筛查策略进行了经济评估。然而，尚未综合筛查研究来为疾病领域的早期检测提供资源分配信息。因此，应系统地审查评估胰腺癌筛查的成本效益和成本的研究。
将对报告胰腺癌筛查的成本效益或成本的经济评估进行系统综述。将无地理和时间限制地在电子数据库 Medline、Web of Science 和 EconLit 中进行搜索。两名独立的审查员将根据预设标准选择合格的研究。使用合并健康经济评估报告标准声明和经济评估偏差清单评估研究质量。一名审查员将提取相关数据，第二名审查员将交叉检查提取表的合规性。关键项目将包括筛查个体的特征、使用的筛查策略以及作为研究结果的成本、健康效果和成本效益。审查员之间的意见分歧将通过咨询第三名审查员来解决。
由于本研究不收集原始数据，因此不需要伦理批准。研究结果将通过会议演示和在同行评议期刊上发表来传播。系统综述的结果将为未来的胰腺癌筛查经济评估提供信息，为医疗保健资源优先排序的决策提供指导。
PROSPERO 注册号：CRD42023475348。
